Industries › Healthcare › Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances)
The 167 US-listed Biological Products, (No Diagnostic Substances) companies we cover, ranked by market cap. Updated
The largest Biological Products, (No Diagnostic Substances) companies by market cap: Amgen, Gilead Sciences, Moderna, Revolution Medicines, Inc., Biogen. Together, the 159 companies we cover report $101.0B in combined trailing-twelve-month revenue — the sum of covered companies' reported revenue, not an industry market-size estimate.
Biological Products, (No Diagnostic Substances) heatmap
Tile size is market cap; color is the latest daily change.
Technical signals in Biological Products, (No Diagnostic Substances)
Chart conditions currently in force among Biological Products, (No Diagnostic Substances) stocks — each opens the screener filtered to Biological Products, (No Diagnostic Substances) + that signal.
Golden Cross Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks whose 50-day moving average has just crossed above the 200-day — a widely-watched long-term trend signal. A live technical scan, refreshed daily — informational, not advice.
Golden Cross screener →New 52-Week High Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks that just printed a fresh 52-week high. A live technical scan, refreshed daily — informational, not advice.
52-week-high screener →Oversold Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks with a 14-day RSI below 30, the level chartists call oversold. A live technical scan, refreshed daily — informational, not advice.
Oversold screener →Overbought Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks with a 14-day RSI above 70 (overbought territory). A live technical scan, refreshed daily — informational, not advice.
Overbought screener →RSI Bounce Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks where the 14-day RSI has just turned up out of oversold. A live technical scan, refreshed daily — informational, not advice.
RSI-bounce screener →Near 52-Week High Biological Products, (No Diagnostic Substances) Stocks
Biological Products, (No Diagnostic Substances) stocks trading within 10% of their 52-week high. A live technical scan, refreshed daily — informational, not advice.
52-week-high screener →Companies
| AMGN | Amgen | 444.20 | +0.31% | $240.1B |
| GILD | Gilead Sciences | 151.21 | +1.09% | $187.5B |
| MRNA | Moderna | 147.40 | -1.94% | $58.8B |
| RVMD | Revolution Medicines, Inc. | 210.79 | +0.76% | $45.2B |
| BIIB | Biogen | 224.49 | +0.78% | $33.1B |
| NBIX | Neurocrine Biosciences Inc | 158.32 | +0.33% | $16.1B |
| EXEL | Exelixis, Inc. | 59.13 | +1.00% | $14.7B |
| HALO | Halozyme Therapeutics, Inc. | 110.73 | +1.01% | $12.6B |
| TECH | Bio-Techne | 72.46 | +0.21% | $11.4B |
| KRYS | Krystal Biotech, Inc. | 371.35 | +0.58% | $11.0B |
| APGE | Apogee Therapeutics, Inc. | 135.08 | +0.04% | $10.2B |
| KYMR | Kymera Therapeutics, Inc. | 117.15 | -1.24% | $9.7B |
| RGEN | Repligen Corp | 169.68 | -1.87% | $9.6B |
| PCVX | Vaxcyte, Inc. | 61.22 | -0.62% | $9.1B |
| IBRX | Immunitybio, Inc. | 8.16 | +2.90% | $8.6B |
| IMVT | Immunovant, Inc. | 39.10 | -0.96% | $8.1B |
| TWST | Twist Bioscience Corp | 128.68 | -1.77% | $8.1B |
| SRRK | Scholar Rock Holding Corp | 55.91 | -0.42% | $6.8B |
| CGON | Cg Oncology, Inc. | 74.31 | -0.41% | $6.6B |
| CRSP | Crispr Therapeutics Ag | 56.47 | -0.79% | $5.5B |
| RLAY | Relay Therapeutics, Inc. | 19.00 | +2.67% | $4.2B |
| IOVA | Iovance Biotherapeutics, Inc. | 8.80 | +2.09% | $4.0B |
| ADPT | Adaptive Biotechnologies Corp | 24.57 | -0.34% | $3.9B |
| TARS | Tarsus Pharmaceuticals, Inc. | 83.12 | +0.41% | $3.6B |
| DNLI | Denali Therapeutics Inc. | 22.80 | -0.33% | $3.6B |
| BEAM | Beam Therapeutics Inc. | 29.45 | +0.53% | $3.0B |
| BCRX | Biocryst Pharmaceuticals Inc | 10.10 | -0.79% | $2.6B |
| KOD | Kodiak Sciences Inc. | 36.36 | -3.10% | $2.3B |
| ADMA | Adma Biologics, Inc. | 9.59 | +0.63% | $2.1B |
| VCEL | Vericel Corp | 40.49 | -0.92% | $2.1B |
| COAG | Hemab Therapeutics Holdings, Inc. | 44.29 | -1.06% | $2.1B |
| VIR | Vir Biotechnology, Inc. | 11.45 | -0.48% | $1.9B |
| RXRX | Recursion Pharmaceuticals, Inc. | 3.43 | +1.63% | $1.8B |
| TSHA | Taysha Gene Therapies, Inc. | 5.57 | -1.24% | $1.8B |
| INBX | Inhibrx Biosciences, Inc. | 121.90 | -1.92% | $1.8B |
| NVAX | Novavax Inc | 10.34 | +0.19% | $1.7B |
| REPL | Replimune Group, Inc. | 15.28 | -4.32% | $1.4B |
| MAZE | Maze Therapeutics, Inc. | 25.90 | -3.07% | $1.4B |
| VOR | Vor Biopharma Inc. | 24.22 | -2.73% | $1.4B |
| CGEM | Cullinan Therapeutics, Inc. | 22.16 | -0.81% | $1.4B |
| MGTX | Meiragtx Holdings Plc | 13.96 | -0.68% | $1.3B |
| ODTX | Odyssey Therapeutics, Inc. | 26.38 | -0.90% | $1.3B |
| GLUE | Monte Rosa Therapeutics, Inc. | 14.39 | +1.12% | $1.2B |
| SANA | Sana Biotechnology, Inc. | 3.92 | +0.51% | $1.2B |
| ATTO | Attovia Therapeutics, Inc. | 25.33 | +3.56% | $1.2B |
| SLDB | Solid Biosciences Inc. | 10.42 | +1.36% | $1.1B |
| CADL | Candel Therapeutics, Inc. | 12.96 | -1.67% | $992M |
| FDMT | 4d Molecular Therapeutics, Inc. | 14.70 | -1.64% | $812M |
| AURA | Aura Biosciences, Inc. | 7.38 | -1.93% | $765M |
| GRML | Greenland Mines Ltd | 4.50 | -7.31% | $715M |
| ALLO | Allogene Therapeutics, Inc. | 1.98 | +0.25% | $682M |
| PRME | Prime Medicine, Inc. | 3.71 | +0.82% | $673M |
| RGNX | Regenxbio Inc. | 9.19 | -4.27% | $607M |
| EIKN | Eikon Therapeutics, Inc. | 10.92 | -4.08% | $591M |
| CABA | Cabaletta Bio, Inc. | 3.48 | -2.80% | $589M |
| TECX | Tectonic Therapeutic, Inc. | 29.89 | -1.60% | $584M |
| ZURA | Zura Bio Ltd | 5.88 | +3.52% | $563M |
| SCTX | Scribe Therapeutics, Inc. | 28.81 | -6.55% | $545M |
| ARTV | Artiva Biotherapeutics, Inc. | 11.14 | -1.76% | $545M |
| KYTX | Kyverna Therapeutics, Inc. | 8.33 | -3.31% | $515M |
| EDIT | Editas Medicine, Inc. | 3.08 | +0.00% | $472M |
| CCCC | C4 Therapeutics, Inc. | 3.74 | -1.06% | $460M |
| OCGN | Ocugen, Inc. | 1.34 | +1.52% | $454M |
| DNA | Ginkgo Bioworks Holdings, Inc. | 6.95 | -1.14% | $443M |
| CMPX | Compass Therapeutics, Inc. | 2.37 | -2.87% | $427M |
| XFOR | X4 Pharmaceuticals, Inc | 4.05 | +0.12% | $402M |
| LXEO | Lexeo Therapeutics, Inc. | 4.83 | +1.15% | $397M |
| IPSC | Century Therapeutics, Inc. | 2.08 | -1.89% | $377M |
| AGEN | AGENUS INC | 8.23 | +1.86% | $371M |
| PALI | Palisade Bio, Inc. | 2.04 | +2.25% | $356M |
| IKT | Inhibikase Therapeutics, Inc. | 2.51 | +0.40% | $350M |
| STRO | Sutro Biopharma, Inc. | 20.52 | +0.05% | $340M |
| SABS | SAB Biotherapeutics, Inc. | 3.72 | -1.06% | $338M |
| FATE | FATE THERAPEUTICS INC | 2.42 | -1.22% | $290M |
| ALEC | Alector, Inc. | 2.50 | -8.09% | $279M |
| LCTX | Lineage Cell Therapeutics, Inc. | 1.10 | -0.90% | $278M |
| SRZN | Surrozen, Inc./DE | 22.50 | -0.29% | $265M |
| AVXL | ANAVEX LIFE SCIENCES CORP. | 2.84 | -2.07% | $263M |
| NMRA | Neumora Therapeutics, Inc. | 1.35 | -1.46% | $254M |
| LIMN | Liminatus Pharma, Inc. | 3.70 | -2.89% | $248M |
| IVVD | Invivyd, Inc. | 0.83 | +2.74% | $244M |
| TARA | Protara Therapeutics, Inc. | 3.96 | +0.25% | $234M |
| ABOS | Acumen Pharmaceuticals, Inc. | 3.09 | -0.64% | $223M |
| PLX | Protalix BioTherapeutics, Inc. | 2.62 | +0.77% | $211M |
| CHRS | Coherus Oncology, Inc. | 1.36 | -3.55% | $210M |
| VYGR | Voyager Therapeutics, Inc. | 3.37 | -4.94% | $207M |
| DTIL | PRECISION BIOSCIENCES INC | 7.36 | -1.47% | $203M |
| ARMP | Armata Pharmaceuticals, Inc. | 5.45 | -2.59% | $202M |
| ACOG | Alpha Cognition Inc. | 9.20 | -1.23% | $200M |
| LENZ | LENZ Therapeutics, Inc. | 5.80 | +0.00% | $182M |
| CRBU | Caribou Biosciences, Inc. | 1.56 | -1.89% | $167M |
| HUMA | Humacyte, Inc. | 0.60 | +0.08% | $166M |
| OTLK | Outlook Therapeutics, Inc. | 0.65 | +3.48% | $159M |
| TNYA | Tenaya Therapeutics, Inc. | 0.70 | -0.24% | $156M |
| ENGN | enGene Therapeutics Inc. | 1.82 | -3.96% | $122M |
| BDTX | Black Diamond Therapeutics, Inc. | 2.11 | -1.40% | $121M |
| PROK | PROKIDNEY CORP. | 1.92 | +0.26% | $118M |
| CGTX | COGNITION THERAPEUTICS INC | 1.06 | +0.00% | $101M |
| PTHS | Pelthos Therapeutics Inc. | 25.08 | +0.52% | $96M |
| ATRA | Atara Biotherapeutics, Inc. | 9.44 | +0.53% | $95M |
Frequently asked questions
How many Biological Products, (No Diagnostic Substances) companies are there?
We cover 167 US-listed Biological Products, (No Diagnostic Substances) companies as of 2026-09-18, refreshed every trading day.
Who are the largest Biological Products, (No Diagnostic Substances) companies?
By market cap, the largest Biological Products, (No Diagnostic Substances) companies we cover are Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA).
What is the combined market cap of the Biological Products, (No Diagnostic Substances) industry?
The 167 US-listed Biological Products, (No Diagnostic Substances) companies we cover have a combined market capitalization of $789.4 billion as of 2026-09-18.
What is the total revenue of the Biological Products, (No Diagnostic Substances) industry?
The combined trailing-twelve-month revenue of the US-listed Biological Products, (No Diagnostic Substances) companies we cover is $101.0 billion. This is the sum of covered companies' reported revenue — not an industry market-size estimate.
What is the average dividend yield of Biological Products, (No Diagnostic Substances) companies?
The cap-weighted average dividend yield of the Biological Products, (No Diagnostic Substances) stocks we cover is 2.06%.
Industry classification from SEC EDGAR (SIC) · Databento EQUS.MINI (prices) · combined figures are sums/averages of the US-listed companies we cover. Informational only — not financial advice.